about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

De­sert­ed by Sanofi, Lex­i­con dis­clos­es last-minute hic­cup in its so­lo fight to get so­tagliflozin ap­proved

4 years ago
FDA+

Safe­ty con­cerns cause GSK to stop high­ly an­tic­i­pat­ed vac­cine tri­al in sur­prise set­back

4 years ago
R&D
Pharma

De­vel­op­ers of a key mR­NA de­liv­ery tech, seek­ing a piece of Mod­er­na's Covid rich­es, sue for patent in­fringe­ment

4 years ago
Pharma
Law

Biosim­i­lars unite: Look­ing for com­mer­cial con­sol­i­da­tion, Bio­con buys out long­time part­ner Vi­a­tris for $3.3B

4 years ago
Deals

Lat­est news on J&J's ma­jor court win; Ukraine's place in biotech; Man­ag­ing ex­pec­ta­tions for AI; Lil­ly ups its RNA ...

4 years ago
Weekly

Watch out, No­var­tis: Eli Lil­ly, Boehringer In­gel­heim notch broad heart fail­ure OK for Jar­diance

4 years ago
Pharma
FDA+

Pfiz­er drops case against ex-staffer ac­cused of steal­ing trade se­crets — in­clud­ing de­tails about Covid-19 vac­cine

4 years ago
People
Pharma

DOJ scraps di­vi­sive Chi­na Ini­tia­tive that swept up promi­nent sci­en­tists — but vows to keep guard­ing against ...

4 years ago
People
China

Sanofi, GSK prep reg­u­la­to­ry fil­ings for Covid-19 vac­cine af­ter post­ing PhI­II, boost­er da­ta — but who will use it?

4 years ago
R&D
Coronavirus

They made the first an­ti-VEGF drug 20+ years ago. Now two long­time part­ners have $65M to spot new eye drugs

4 years ago
Financing
Startups

As long­time CMO ex­its, Karyopharm taps Big Phar­ma vets to steer can­cer drug fran­chise

4 years ago
People

Biotech shares evis­cer­at­ed in wake of Covid-19 flop

4 years ago
R&D

Claim­ing his­toric first, As­traZeneca says En­her­tu aces PhI­II for hard-to-reach seg­ment of pa­tients

4 years ago
R&D

In­side PBM­s' tac­tics to tilt the mar­ket; Is the KRAS race still on? CAR-T safe­ty scares trig­ger halts; and more

4 years ago
Weekly

In sur­prise flop, Re­gen­eron, Sanofi re­port Dupix­ent PhI­II fail­ure, trig­ger­ing pre­ma­ture tri­al stop

4 years ago
R&D

Flash­ing red on RSV ma­ter­nal vac­cine, GSK paus­es PhI­II tri­al fol­low­ing ‘ob­ser­va­tion’ from safe­ty check

4 years ago
R&D

Covid-19 roundup: Pfiz­er, BioN­Tech's Omi­cron-spe­cif­ic shot de­layed as surge wanes, while Mod­er­na eyes Au­gust roll­out

4 years ago
Coronavirus

In wake of Lan­der res­ig­na­tion, Biden taps Fran­cis Collins, Alon­dra Nel­son to fill top sci­ence roles

4 years ago
People

Some genes are too large to fit in­to AAV vec­tors. UCB, No­var­tis back $57M idea to de­liv­er them in parts in­stead

4 years ago
Financing
Startups

Hunt­ing deals on all fronts, Mer­ck en­lists drug dis­cov­ery biotech on search for pro­tein mod­u­la­tors

4 years ago
Deals

Mod­er­na turns to Asia, plots new hires as it pon­ders $35B+ Covid-19 vac­cine wind­fall

4 years ago
Coronavirus

Gilead re­jigs HIV im­munother­a­py pact, grabs a stake in biotech part­ner

4 years ago
Deals

FDA hits Leg­end Biotech with clin­i­cal hold on CAR-T just days ahead of BC­MA de­ci­sion

4 years ago
FDA+

AI start­up grabs $60M, un­veils plat­form aimed at drug dis­cov­ery's 'da­ta prob­lem'

4 years ago
Financing
Startups
First page Previous page 36373839404142 Next page Last page
A service from the Financial Times